# The Citric Acid Cycle Modulates Neurologic Health and Is a Therapeutic Target of Dietary and Genetic Modification in Metabolic Disease

**Authors:** Keri J. Fogle, Sarah K. Lindley, Sidney L. Satterfield, Beakal A. Amsalu, Joseph R. Figura, Samantha L. Eicher, Luke A. Scherz, Michael J. Palladino

PMC · DOI: 10.3390/genes17020192 · Genes · 2026-02-04

## TL;DR

The citric acid cycle plays a key role in neurological health and could be a target for treating metabolic and neurodegenerative diseases.

## Contribution

The study reveals a new role of the citric acid cycle in maintaining circadian rhythms and neurological function.

## Key findings

- Stimulating the citric acid cycle improves neurological health in metabolic disease models.
- The CAC helps maintain normal circadian rhythms, which are linked to neurological disorders.
- GTP production by the CAC may be a key mechanism in its therapeutic potential for neurological diseases.

## Abstract

Background/Objectives: Primary metabolic diseases including mitochondrial encephalomyopathies (ME), glycolytic enzymopathies, and disorders of lipid and amino acid metabolism can manifest with severe neurological and neuromuscular symptoms. Conversely, it is increasingly appreciated that primary neurodegenerative diseases can have metabolic etiology and pathophysiology. Pharmacological treatments have limited benefit for these classes of diseases, but dietary therapy is increasingly recognized as a tool for bolstering metabolic processes that can ameliorate neurological symptoms. The ketogenic diet is the best-established example, having long been used as a therapy for epilepsy. Replenishing metabolic intermediates (anaplerosis) especially substrates of the citric acid cycle (CAC) is currently being explored, with ongoing clinical trials of simple metabolic intermediates such as oxaloacetate or NAD+ to treat neurodegenerative diseases. We have shown ketogenic and anaplerotic therapies to be effective in a Drosophila model of ME; however, the full therapeutic potential and role of the CAC in neuronal health is still not well understood. Methods: Here, we have used genetic, behavioral, and dietary approaches to elucidate critical links between the CAC and neurological function. Results: We have found that stimulating the CAC can improve and sustain neurological health in the face of severe metabolic disease, and that its functions include a previously unrecognized role in maintaining normal circadian rhythms, whose disruption is often an early indicator or complicating factor in neurological and neurodegenerative disease. We investigated the hypothesis that the production of GTP by the CAC may be an important mechanistic contributor to the role of the CAC in neurological health and disease, and may underlie its therapeutic potential. Conclusions: Overall, our findings expand our understanding of the role of the CAC in neurological health and disease, support its development as a therapeutic target, and provide a foundation for further studies investigating the intersection between neurological disease and metabolic function.

## Linked entities

- **Chemicals:** oxaloacetate (PubChem CID 970), NAD+ (PubChem CID 5892)
- **Diseases:** epilepsy (MONDO:0005027)
- **Species:** Drosophila (taxon 7215)

## Full-text entities

- **Genes:** ME2 (malic enzyme 2) [NCBI Gene 4200] {aka ODS1}, TTR (transthyretin) [NCBI Gene 7276] {aka AMYLD1, ATTR, CTS, CTS1, HEL111, HsT2651}, cac (cacophony) [NCBI Gene 32158] {aka 13, CG1522, CG15928, CG43368, Ca-alpha1A, Ca[[V]]2.1}, IDH1 (isocitrate dehydrogenase (NADP(+)) 1) [NCBI Gene 3417] {aka HEL-216, HEL-S-26, IDCD, IDH, IDP, IDPC}, ATP6 (F1F0 ATP synthase subunit a) [NCBI Gene 854601] {aka OLI2, OLI4, PHO1}, FH (fumarate hydratase) [NCBI Gene 2271] {aka FMRD, HLRCC, HsFH, LRCC, MCL, MCUL1}, CLOCK (clock circadian regulator) [NCBI Gene 9575] {aka KAT13D, bHLHe8}, ATP6 (ATP synthase F0 subunit 6) [NCBI Gene 4508] {aka ATPase6, MTATP6}, CA2 (carbonic anhydrase 2) [NCBI Gene 760] {aka CA-II, CAC, CAII, Car2, HEL-76, HEL-S-282}, kdn (knockdown) [NCBI Gene 31579] {aka BEST:GM01832, CG 3861, CG3861, CS, Csyn, Dmel\CG3861}, TPI1 (triosephosphate isomerase 1) [NCBI Gene 7167] {aka HEL-S-49, TIM, TPI, TPID}, CMPK2 (cytidine/uridine monophosphate kinase 2) [NCBI Gene 129607] {aka IBGC10, NDK, TMPK2, TYKi, UMP-CMPK2}
- **Diseases:** FBSN (MESH:C537500), cardiovascular and gastrointestinal side effects (MESH:D064420), epilepsies (MESH:D004827), ME (MESH:D017237), or mobility issues (MESH:D014086), ataxia (MESH:D001259), intellectual disability (MESH:D008607), death (MESH:D003643), disorders of lipid and amino acid metabolism (MESH:D052439), ketosis (MESH:D007662), neuromuscular dysfunction (MESH:D009468), LS (MESH:D007888), glucose hypometabolism (MESH:D018149), neurological and neuromuscular symptoms (MESH:D020879), Neuropathy (MESH:D009422), cognitive or sensory impairment (MESH:D003072), Ataxia Retinitis Pigmentosa (MESH:C537396), muscle degeneration (MESH:D009410), dementia (MESH:D003704), developmental delay or regression (MESH:C537770), lactic acidosis (MESH:D000140), temporal lobe epilepsy (MESH:D004833), locomotor impairment (MESH:D001523), AD (MESH:D000544), mitochondrial disruption (MESH:D019958), neurological defects (MESH:D009421), dystonia (MESH:D004421), neurodegenerative diseases (MESH:D019636), injury to (MESH:D014947), PD (MESH:D010300), mitochondrial disease (MESH:D028361), disordered sleep (MESH:D012893), vision problems (MESH:D014786), NDPK (MESH:C562587), neurological (MESH:D009461), circadian rhythm defects (MESH:D021081), Seizure (MESH:D012640), Metabolic Disease (MESH:D008659), Neurological and neurodegenerative diseases (MESH:D020271), paralysis (MESH:D010243)
- **Chemicals:** phosphoric acid (MESH:C030242), NADP (MESH:D009249), THP (MESH:C531010), acetoacetyl-CoA (MESH:C010667), Oxa (MESH:D062907), coconut oil (MESH:D000074263), NMN (MESH:D009537), succinyl CoA (MESH:C012046), carbohydrate (MESH:D002241), fatty acid (MESH:D005227), acetoacetate (MESH:C016635), Pentadecanoic acid (MESH:C117025), hydrogen peroxide (MESH:D006861), Anaplerotic (-), alpha-ketoglutarate (MESH:D007656), tryptophan (MESH:D014364), fumarate (MESH:D005650), dopamine (MESH:D004298), NAD (MESH:D009243), ROS (MESH:D017382), FADH2 (MESH:C058805), paraquat (MESH:D010269), serotonin (MESH:D012701), dextrose (MESH:D005947), Citric Acid (MESH:D019343), glutathione (MESH:D005978), rotenone (MESH:D012402), methylglyoxal (MESH:D011765), ATP (MESH:D000255), MPTP (MESH:D015632), sucrose (MESH:D013395), Lipid (MESH:D008055), lactic acid (MESH:D019344), Flavins (MESH:D005415), pentose phosphate (MESH:D010428), triglyceride (MESH:D014280), ketone (MESH:D007659), agar (MESH:D000362), fats (MESH:D005223), Pyr (MESH:D019289), GTP (MESH:D006160), succinate (MESH:D019802), acid (MESH:D000143), phosphate (MESH:D010710), glutamate (MESH:D018698), GABA (MESH:D005680), norepinephrine (MESH:D009638), LA (MESH:C030358), ketone bodies (MESH:D007657), propionic acid (MESH:C029658), acetyl-CoA (MESH:D000105)
- **Species:** Homo sapiens (human, species) [taxon 9606], Diptera (flies, order) [taxon 7147], Drosophila melanogaster (fruit fly, species) [taxon 7227], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932]
- **Mutations:** glycine to glutamate amino acid substitution at position 116

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940393/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940393/full.md

## References

84 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940393/full.md

---
Source: https://tomesphere.com/paper/PMC12940393